JP2020513810A - クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ - Google Patents

クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ Download PDF

Info

Publication number
JP2020513810A
JP2020513810A JP2019550762A JP2019550762A JP2020513810A JP 2020513810 A JP2020513810 A JP 2020513810A JP 2019550762 A JP2019550762 A JP 2019550762A JP 2019550762 A JP2019550762 A JP 2019550762A JP 2020513810 A JP2020513810 A JP 2020513810A
Authority
JP
Japan
Prior art keywords
yap
individual
heart
yap5sa
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513810A5 (enExample
Inventor
モンロー、タナー
リーチ、ジョン
マーティン、ジェームズ、エフ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of JP2020513810A publication Critical patent/JP2020513810A/ja
Publication of JP2020513810A5 publication Critical patent/JP2020513810A5/ja
Priority to JP2022105207A priority Critical patent/JP7461071B2/ja
Priority to JP2024040081A priority patent/JP2024073571A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
JP2019550762A 2017-03-14 2018-03-14 クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ Pending JP2020513810A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022105207A JP7461071B2 (ja) 2017-03-14 2022-06-30 クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ
JP2024040081A JP2024073571A (ja) 2017-03-14 2024-03-14 クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471204P 2017-03-14 2017-03-14
US62/471,204 2017-03-14
PCT/US2018/022496 WO2018170172A1 (en) 2017-03-14 2018-03-14 Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105207A Division JP7461071B2 (ja) 2017-03-14 2022-06-30 クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ

Publications (2)

Publication Number Publication Date
JP2020513810A true JP2020513810A (ja) 2020-05-21
JP2020513810A5 JP2020513810A5 (enExample) 2021-04-15

Family

ID=63523973

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019550762A Pending JP2020513810A (ja) 2017-03-14 2018-03-14 クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ
JP2022105207A Active JP7461071B2 (ja) 2017-03-14 2022-06-30 クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ
JP2024040081A Pending JP2024073571A (ja) 2017-03-14 2024-03-14 クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022105207A Active JP7461071B2 (ja) 2017-03-14 2022-06-30 クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ
JP2024040081A Pending JP2024073571A (ja) 2017-03-14 2024-03-14 クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ

Country Status (10)

Country Link
US (3) US11484553B2 (enExample)
EP (1) EP3595642A4 (enExample)
JP (3) JP2020513810A (enExample)
CN (2) CN116003564A (enExample)
AU (2) AU2018234632B2 (enExample)
BR (1) BR112019018912A2 (enExample)
CA (1) CA3056231A1 (enExample)
IL (2) IL308112B2 (enExample)
MX (2) MX2019010986A (enExample)
WO (1) WO2018170172A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634495A4 (en) * 2017-06-01 2021-02-24 Baylor College of Medicine Dystrophin glycoprotein complex sequesters yap to inhibit cardiomyocyte proliferation
US11179479B2 (en) 2018-01-05 2021-11-23 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
WO2021119030A1 (en) * 2019-12-09 2021-06-17 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
US20210324412A1 (en) * 2020-04-15 2021-10-21 University Of Southern California Activation of yap signaling for sensory receptor regeneration
CN111778281B (zh) * 2020-07-17 2021-04-23 四川省人民医院 一种视网膜双极细胞病变模型的构建方法及其应用
US20230193267A1 (en) * 2021-10-19 2023-06-22 Animatus Biosciences, Inc. Cardiac cell proliferation by administering inhibitors of sav1, nf2, mob1 and/or mutant srf
WO2024168269A1 (en) * 2023-02-10 2024-08-15 Baylor College Of Medicine Use of mutant yap for improving cardiac function

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090287724A1 (en) * 2008-05-15 2009-11-19 Microsoft Corporation Data Viewer Management
US20160287724A1 (en) * 2013-11-18 2016-10-06 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
TW563139B (en) 2000-11-30 2003-11-21 Nec Tokin Corp Magnetic core including magnet for magnetic bias and inductor component using the same
KR101057116B1 (ko) 2008-06-17 2011-08-16 한국과학기술원 포유류에서의 분화 조절제 및 분화 조절 방법
AU2013243952A1 (en) * 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CN103705505A (zh) * 2013-12-19 2014-04-09 清华大学深圳研究生院 辛伐他汀的新用途
US20160361340A1 (en) * 2014-02-11 2016-12-15 Inetitut Pasteur Treatment of cardiac diseases with modulators of the hippo pathway
US20170246215A1 (en) * 2014-09-16 2017-08-31 Albert Einstein College Of Medicine, Inc. Repopulation of organs and tissues using a yap-ert2 fusion protein
GB201819659D0 (en) * 2018-12-03 2019-01-16 Vib Vzw Cancer regression by inducing a regeneration-like reponse

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090287724A1 (en) * 2008-05-15 2009-11-19 Microsoft Corporation Data Viewer Management
US20160287724A1 (en) * 2013-11-18 2016-10-06 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. 69, no. 3, JPN6022000646, 2009, pages 1089 - 1098, ISSN: 0004881571 *
CIRCULATION RESEARCH, vol. 115, JPN6022000651, 2014, pages 354 - 363, ISSN: 0004881567 *
GENES & DEVELOPMENT, vol. 24, no. 1, JPN6022000648, 2010, pages 72 - 85, ISSN: 0004881570 *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, U.S.A, vol. 109, no. 7, JPN6022000642, 2012, pages 2394 - 2399, ISSN: 0004881568 *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, U.S.A, vol. 110, no. 34, JPN6022000641, 2013, pages 13839 - 13844, ISSN: 0004881569 *
STEM CELL RESEARCH, vol. 13, JPN6022000644, 2014, pages 571 - 581, ISSN: 0004678161 *

Also Published As

Publication number Publication date
BR112019018912A2 (pt) 2020-04-14
CN110520112A (zh) 2019-11-29
US20230063735A1 (en) 2023-03-02
IL308112A (en) 2023-12-01
JP2024073571A (ja) 2024-05-29
IL269187B2 (en) 2024-04-01
US20250073276A1 (en) 2025-03-06
WO2018170172A1 (en) 2018-09-20
IL308112B2 (en) 2025-01-01
EP3595642A4 (en) 2021-05-26
MX2022011881A (es) 2022-11-09
IL269187A (en) 2019-11-28
CA3056231A1 (en) 2018-09-20
US20200016212A1 (en) 2020-01-16
US12138284B2 (en) 2024-11-12
AU2018234632B2 (en) 2024-06-13
CN116003564A (zh) 2023-04-25
JP7461071B2 (ja) 2024-04-03
US11484553B2 (en) 2022-11-01
AU2024219497B2 (en) 2025-08-14
AU2024219497A1 (en) 2024-10-03
IL308112B1 (en) 2024-09-01
JP2022164658A (ja) 2022-10-27
AU2018234632A1 (en) 2019-10-03
IL269187B1 (en) 2023-12-01
MX2019010986A (es) 2020-02-05
EP3595642A1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
JP7461071B2 (ja) クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ
US20250360129A1 (en) Compositions and methods of using tyrosine kinase inhibitors
US20200316038A1 (en) Methods and compositions for treating urea cycle disorders, in particular otc deficiency
Choi et al. Elevated dual specificity protein phosphatase 4 in cardiomyopathy caused by lamin A/C gene mutation is primarily ERK1/2-dependent and its depletion improves cardiac function and survival
US20230201244A1 (en) Compositions and methods for preventing and/or treating microbial infections
US20220168316A1 (en) Methods and compositions for treating urea cycle disorders
US20240197760A1 (en) Activators of integrated stress response pathway for protection against ferroptosis
US20250144034A1 (en) Modified extracellular vesicles that specifically target kidneys and methods of preparation and applications thereof
CN118697878B (zh) Cd36作为抑制肺癌脑膜转移的分子标志物和治疗靶点的应用
EP4025197A1 (en) Inhibitors of sglt and uses thereof
Nayakanti Role of FoxO3 transcription factor in right ventricular remodeling and failure
US20210145890A1 (en) Dystrophin glycoprotein complex sequesters yap to inhibit cardiomyocyte proliferation
US20250186546A1 (en) Compositions and Methods to Prevent, Inhibit or Treat Autoimmune and Vascular Disease
Cruz Cruz The Role of MDM2 in Mouse Development and its Implication in the Pathogenesis of Cancer and Developmental Diseases
Cruz The Role of MDM2 in Mouse Development and its Implication in the Pathogenesis of Cancer and Developmental Diseases
Auzmendi Iriarte Role of Chaperone-Mediated Autophagy and Histone Deacetylases in Glioblastoma and Brain Aging-A focus on Stem Cell Maintenance.
JP2025161062A (ja) 単離ミトコンドリアを含む薬学的組成物及び胃癌の処置におけるその使用
WO2025050066A1 (en) Compositions including small-molecule tert activator compounds and uses thereof
WO2021183814A1 (en) Metabolites released from apoptotic cells act as novel tissue messengers
Kumar et al. An Intermittent Fasting Mimetic Drives Plasticity Via an Adaptive ER Stress-ATF4 Pathwayand Elicits Stroke Recovery and Alzheimer's Resilience

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210302

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220630

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220927